Tag: competition

HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx¹.

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response

TORONTO, June 13, 2025 (GLOBE NEWSWIRE) -- Rivalry Corp. (the “Company” or “Rivalry”) (TSXV: RVLY) (OTCQX: RVLCF) (FSE: 9VK), is providing this bi-weekly update on the status of a management cease trade order granted on May 1, 2025 (the "MCTO") by its principal regulator, the Ontario Securities Commission (the "OSC"), under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203"). On May 2, 2025, the Company announced that there would be a delay in the filing of its annual financial statements, management’s discussion and analysis and related CEO and CFO certificates for the fiscal year ended December 31, 2024 (collectively, the “Annual Filings”), as required under applicable Canadian securities laws (the "Default Announcement"). As stated in the Default Announcement, the Company expects to complete the Annual Filings by June 30, 2025.

Industry Veteran to Join Global Impact Leaders in Psychedelic Innovation Workshop at World’s Largest Psychedelic Conference

MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard^® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medical Device Regulation (MDR) for the CGuard^® Prime EPS.